Recombinant SARS-CoV-2 ORF7a Fc Chimera Protein, CF

• Reactivity: V
• Format: Carrier-Free

Recombinant SARS-CoV-2 ORF7a Fc Chimera Protein, CF Summary

• Source: Chinese Hamster Ovary cell line, CHO-derived sars-cov-2 ORF7a protein
  

  SARS-CoV-2 ORF7a (Glu16-Leu96) Accession # YP_009724395.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: YP_009724395.1
• N-terminal Sequence: Glu16
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Theoretical MW: 36 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 37-42 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in Tris, NaCl, TCEP and Glycerol.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant SARS-CoV-2 ORF7a Fc Chimera Protein, CF

• ORF7a

Background

Open Reading Frame 7a (ORF7a) is one of eight accessory proteins encoded at the 3' region of the coronavirus (CoV) genome (1). The accessory proteins are largely dispensable for viral replication and growth in vitro (2,3). Although not essential for replication the accessory proteins are thought to modulate virus-host interactions that are important during infection (4). Coronaviruses include various highly pathogenic strains such as SARS-CoV, MERS-CoV and SARS-CoV2 that have had significant impact on humans as well as strains that have negatively impacted livestock. ORF7a from SARS-CoV2 is a small 121 amino acid (aa) type I transmembrane protein (5,6). ORF7a contains an N-terminal signal peptide, a luminal domain, transmembrane domain, and a short C-terminal cytoplasmic tail that functions as an ER export signal (5,7). It is expressed and retained intracellularly in cells infected with SARS-CoV and primarily localized to the Golgi (5,7) Although the function of the accessory proteins has not been well-defined, ORF7a has been shown to activate p38 MAPK(7), NF-kB, and JNK signaling pathways, enhance production of inflammatory chemokines known to be upregulated in SARS-CoV infection (8), and inhibit cellular protein synthesis (9). These reports indicate ORF7a may be involved in the inflammatory response and induction of apoptosis of SARS-CoV infected cells (7-10). ORF7a has also been reported to bind and prevent glycosylation of host cell protein bone marrow stromal antigen 2 (BST-2). Binding inhibits BST-2's ability to block the release of SARS-CoV virions (11). Therapeutics designed to inhibit the interaction of the ectodomain of ORF7a and BST2 have been proposed as a method to inhibit virus growth (11).

1. Hartenian, E. et al. (2020) J. Biol. Chem. 295:12910.
2. Haijema, B.J. et al. (2004) J. Virol. 78:3863.
3. Yount, B. et al. (2005) J. Virol. 79:14909.
4. Liu, D.X. et al. (2014) Antiviral Res. 109:97.
5. Nelson, C.A. et al. (2005) Structure 13:75.
6. Yoshimoto, F.K. et al. (2020) Protein J. 39:198.
7. Schaecher, S.R. et al. (2007) J. Virol. 81:11054.
8. Kanzawa, N. et al. (2006) FEBS Lett. 580:6807.
9. Kopecky-Bromberg, S.A. et al. (2006) J. Virol. 80:785.
10. Tan, Y. et al. (2004) J. Virol. 78:14043.
11. Taylor, J.K. et al. (2015) J. Virol. 89:11820.

Bioinformatics

• Uniprot:
  • YP_009724395.1()